Follow
'A key feature of the accelerated approval system is that manufacturers are required to conduct post-approval studies to demonstrate the drug’s therapeutic value. Among 93 cancer drug indications granted accelerated approval between 1992 and 2017, confirmatory trials reported an overall survival improvement in only 20% of them.'
